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Abstract
Background: The lantibiotic mersacidin is an antimicrobial peptide of 20 amino acids that is
ribosomally produced by Bacillus sp. strain HIL Y-85,54728. Mersacidin acts by complexing the sugar
phosphate head group of the peptidoglycan precursor lipid II, thereby inhibiting the
transglycosylation reaction of peptidoglycan biosynthesis.
Results: Here, we studied the growth of Staphylococcus aureus in the presence of subinhibitory
concentrations of mersacidin. Transcriptional data revealed an extensive induction of the cell wall
stress response, which is partly controlled by the two-component regulatory system VraSR. In
contrast to other cell wall-active antibiotics such as vancomycin, very low concentrations of
mersacidin (0.15 × MIC) were sufficient for induction. Interestingly, the cell wall stress response
was equally induced in vancomycin intermediately resistant S. aureus (VISA) and in a highly
susceptible strain. Since the transcription of the VraDE ABC transporter genes was induced up to
1700-fold in our experiments, we analyzed the role of VraDE in the response to mersacidin.
However, the deletion of the vraE gene did not result in an increased susceptibility to mersacidin
compared to the wild type strain. Moreover, the efficacy of mersacidin was not affected by an
increased cell wall thickness, which is part of the VISA-type resistance mechanism and functions by
trapping the vancomycin molecules in the cell wall before they reach lipid II. Therefore, the
relatively higher concentration of mersacidin at the membrane might explain why mersacidin is
such a strong inducer of VraSR compared to vancomycin.
Conclusion: In conclusion, mersacidin appears to be a strong inducer of the cell wall stress
response of S. aureus at very low concentrations, which reflects its general mode of action as a cell
wall-active peptide as well as its use of a unique target site on lipid II. Additionally, mersacidin does
not seem to be a substrate for the resistance transporter VraDE.
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Background
Lantibiotics form a particular group among the antimicro-
bial peptides (AMPs) and are characterized by unique
structural features. These result from extensive posttrans-
lational modifications that yield the ring forming
thioether amino acids lanthionine and/or 3-methyllan-
thionine. The ring structures contribute to enhanced
resistance towards proteolysis [1] and to increased toler-
ance to oxidizing conditions [2]. In fact, the designation
"lantibiotics" is derived from "lanthionine containing
antibiotics". Lantibiotics are produced by and act against
Gram-positive bacteria and exert multiple modes of
action like pore formation and/or inhibition of cell wall
biosynthesis [3-5]. Mersacidin is the smallest lantibiotic
known so far (1825 Da) and is produced by Bacillus sp.
strain HIL Y-85,54728. It is an uncharged molecule of 20
amino acids forming four intramolecular thioether
bridges, which confer a globular structure to the molecule
[6]. Mersacidin inhibits the transglycosylation reaction of
cell wall biosynthesis by complexing the sugar phosphate
head group of the peptidoglycan precursor lipid II,
thereby using a target binding site that is different from
any other clinically used antibiotic [7]. It has been shown
to successfully inhibit the growth of Gram-positive bacte-
ria including methicillin-resistant Staphylococcus aureus
strains (MRSA) in vitro and in vivo [8-10].
The glycopeptide vancomycin has been the antibiotic of
choice to treat infections with MRSA and acts by binding
the D-alanyl-D-alanine terminus of the peptide side chain
of lipid II. Considering the emergence of vancomycin
intermediately resistant S. aureus strains (VISA) since the
late 1990s [11], new effective treatment strategies for
MRSA are urgently needed. In this context, lantibiotics
could represent alternatives for clinical applications [4]
and mersacidin might be a blueprint for the development
of new antibiotics to control nosocomial infections [7,9].
Previous gene expression studies of Kuroda et al. and Uta-
ida et al. concerning the S. aureus responses to the cell
wall-active substances vancomycin [12], oxacillin, baci-
tracin and D-cycloserine [13] identified a cell wall stress
stimulon, which seems to be predominantly regulated by
the VraSR two-component regulatory system (TCRS).
Members of this stimulon comprise the vraSR  genes
together with genes related to the cell wall metabolism of
S. aureus like  murZ,  uppS,  bacA,  pbp2,  sgtB  and genes
related to protein metabolism. Hence, the VraSR TCRS has
been shown to positively regulate the important steps of
the cell wall biosynthesis pathway as a response to cell
wall stress [12]. Recently, McAleese et al. described a core
cell wall stress stimulon of 17 genes by merging their own
results, that had been recorded in the presence of vanco-
mycin, together with the results of Kuroda et al. and Uta-
ida  et al. [12-14]. In conclusion, the cell wall stress
stimulon is characterized through a comprehensive
response that involves manifold cellular processes. This
general cell wall stress response seems to be conserved
among Gram-positive bacteria [15]. Most recently, the
transcriptional profile of the S. aureus response to the lan-
tibiotic nisin has become available [16]. Nisin acts by
lipid II-based pore formation and inhibition of cell wall
biosynthesis [17]. The S. aureus response to nisin (~3 ×
MIC) was relatively moderate and an induction of the cell
wall stress stimulon was not observed.
In our study, we used gene expression profiling by
employing full genome S. aureus microarrays and quanti-
tative Real-Time PCR (qRT-PCR) techniques to elucidate
the transcriptional response of S. aureus to subinhibitory
concentrations of mersacidin. To this end, we employed
three  S. aureus strains providing varying susceptibility
characteristics, namely the vancomycin- and methicillin-
susceptible (VSSA/MSSA) strain S. aureus SG511 as well as
the heterogeneous VISA/MRSA strain S. aureus SA137/93A
and the closely related VISA/MSSA strain S. aureus SA137/
93G [18,19]. Since self-protection against mersacidin is
mediated by an ABC-transporter in the producer strain,
we also assessed the role of the ABC transporter VraDE,
which was upregulated during exposure to mersacidin, to
counteract the action of mersacidin by employing a vraE-
defective mutant of strain SG511 [20]. We further exam-
ined the influence of cell wall thickness on the activity of
mersacidin, because a thickened cell wall is proposed to
be one of the key resistance mechanisms to vancomycin
[18,21,22].
Results and Discussion
Susceptibility of S. aureus SA137/93A, S. aureus SA137/
93G and S. aureus SG511 to mersacidin
The three strains displayed considerable differences in
their susceptibilities to mersacidin. While the growth of S.
aureus SG511 was already inhibited by 1 μg/ml mersaci-
din in BHI medium, the minimal inhibitory concentra-
tions (MIC) of mersacidin against SA137/93A and SA137/
93G were 35 μg/ml and 30 μg/ml in BHI broth, respec-
tively. Notably, the growth retardation occurred 1 hour
after addition of the lantibiotic (Fig. 1).
Transcriptional response of S. aureus in the presence of 
mersacidin
S. aureus SA137/93A and SA137/93G were grown in BHI
broth to an OD600 of 0.5, then subinhibitory concentra-
tions of mersacidin (16 μg/ml, 0.5 × MIC) were added.
Samples were taken 30 minutes (OD600 of ~1) after addi-
tion of mersacidin, before the decreased growth rate
became apparent (Fig. 1). S. aureus SG511 was grown with
1 × MIC of mersacidin to induce a mersacidin-dependent
transcriptional response, since the profile of the growthBMC Microbiology 2008, 8:186 http://www.biomedcentral.com/1471-2180/8/186
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curve of S. aureus SG511 at 1 × MIC was comparable to
that recorded for the VISA strains at 0.5 × MIC (Fig. 1).
Gene expression profiles of the mersacidin-treated S.
aureus strains were compared to non-treated control cells
and displayed extensive changes in gene expression. These
changes were similar for all three tested strains and
involved the transcript levels of 380 genes that were signif-
icantly changed (> 2.5-fold) upon mersacidin treatment
in at least one of the tested strains, with 207 genes exhib-
iting increased transcript levels (see Additional file 1) and
173 genes showing decreased transcript levels (see Addi-
tional file 2).
Mersacidin strongly induced the cell wall stress response of 
S. aureus
In the presence of mersacidin, the induction of the VraSR-
triggered cell wall stress stimulon was one of the most
striking events of gene regulation (see Additional file 1
and Additional file 2) and included 71 genes of the 161
cell wall stress stimulon members [13]. Similarly, 35
genes out of the 46 genes of the VraSR regulon [12] were
upregulated after exposure to mersacidin (Table 1). Fur-
thermore, 16 out of the 17 members of the core cell wall
stress stimulon [14] were differentially expressed after
mersacidin treatment.
The vraSR genes and several cell wall biosynthesis genes
were strongly upregulated, which included the putative
monofunctional glycosyltransferase gene sgtB, the
transpeptidase/transglycosylase gene pbp2 and the UDP-
N-acetylglucosamine 1-carboxylvinyl transferase gene
murZ, as well as tcaA and drp35. The predominant induc-
tion of the glutamate (gltB, rocA) and lysine (asd, dapAB,
dhoM, lysA) amino acid biosynthesis pathways might also
support cell wall biosynthesis, since glutamate and lysine
represent essential components of the peptidoglycan pre-
cursor lipid II. In fact, the disruption of the dap operon or
the lysA gene has been shown to be involved in a decrease
of oxacillin resistance and growth attenuation of S. aureus
[23,24]. Especially in strain SA137/93A, mersacidin treat-
ment induced the transcription of the bacA  and  uppS
genes, which are involved in lipid II carrier regeneration
and synthesis. Expecting the carrier level to be a limiting
factor when lipid II is blocked by mersacidin, an enhanced
availability of carriers might be beneficial for peptidogly-
can synthesis. In consequence of the peptidoglycan bio-
synthesis inhibition, gene expression for cell wall lytic
enzymes (atl, SA0423, SA2100) was negatively affected. In
terms of membrane trafficking, the oligopeptide transport
system genes oppBCDF and the components of the phos-
photransferase system (PTS) were upregulated. While an
increased expression of the PTS may boost the import of
glucose to supply additional energy, the induction of
OppBCDF might support cell wall biosynthesis by the
acquisition of essential amino acids.
Since incubation with 0.5 × MIC of mersacidin was suffi-
cient to massively induce the cell wall stress response, we
further examined the gene expression profile of strain
SA137/93G at even lower concentrations using DNA
microarrays (Table 1). Incubation with 0.15 × MIC (4 μg/
ml, 2.175 μM) of mersacidin was sufficient to significantly
alter the expression of 19 out of 46 genes of the VraSR reg-
ulon [12] (Table 1) and 12 out of 17 genes belonging to
the core cell wall stress stimulon [14]. These results show,
that inhibitory antibiotic concentrations are not an oblig-
atory requirement for the induction of the cell wall stress
stimulon as it is the case for e.g. vancomycin and oxacillin
[14,25,26]. Compared to 0.5 × MIC, the response was
reduced after employing 0.15 × MIC in strain SA137/93G
(Table 1), suggesting a dose-dependent effect on gene
expression.
Induction of vraS transcription by mersacidin
To verify the induction of the cell wall stress response by
the autoregulatory VraSR TCRS [27], overexpression of the
sensor histidine kinase gene vraS was further analyzed via
In vitro growth of S. aureus in the presence of mersacidin Figure 1
In vitro growth of S. aureus in the presence of mersa-
cidin. To assess suitable mersacidin concentrations for 
microarray experiments, the lantibiotic was added to an 
exponentially growing S. aureus culture at an OD600 of ~0.5 
(time point "a"). In the microarray experiments, the cells 
were harvested at an OD600 of ~1 (time point "b") before the 
reduced growth rates of the cultures became visible. S. 
aureus SG511 (black diamonds, 1 μg/ml; white diamonds, 
control); S. aureus SA137/93A (black triangle, 16 μg/ml; white 
triangle, control); S. aureus SA137/93G (black square, 16 μg/
ml; grey square, 4 μg/ml; white square, control).
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Table 1: Significantly regulated genes of the VraSR-dependent cell wall stress response [12] in this study1
N315 ORF Gene Gene product Product function Fold change2
SA137/93A SA137/93G SG511
(0.5 × MIC) (0.5 × MIC) (0.15 × MIC) (1 × MIC)
SA0531 proP proline/betaine transporter homologue Protein transport and 
binding
2.4 2.7 0.6
SA0536 hypothetical protein 30.2 17.1 8.5 26.6
SA0608 hypothetical protein 2.7 3.8 9.2
SA0825 spsA type-I signal peptidase Protein secretion 2.2 1.4 3.9
SA0909 fmtA FmtA, autolysis and methicillin resistance-
related protein
Pathogenic factors 9.3 3.8 6.3 6.3
SA0914 hypothetical protein, similar to chitinase 
B
14.2 3.9 15.3
SA0931 hypothetical protein 4.9 3.2 6.2
SA1183 opuD glycine betaine transporter Protein transport and 
binding
0.9 0.5 0.5
SA1255 PTS system, glucose-specific enzyme IIA 
component
Protein transport and 
binding
4.7 10.7 2.6 13.1
SA1282 recU recombination protein U homologue DNA recombination 3.6 2.5 2.2 2.5
SA1283 pbp2 penicillin-binding protein 2 Cell wall related genes 3.4 2.3 2.7 3.5
SA1476 hypothetical protein 11.5 11.3 6.5 15.9
SA1548 hypothetical protein, similar to 
acylglycerol- 3-phosphate-O-
acyltransferase homologue
Metabolism of lipids 0.7 0.5 0.6
SA1549 heat-shock protein homologue, similar to 
serine proteinase
Adaptation to atypical 
conditions
7.1 4.6 3.9 5.6
SA1657 conserved hypothetical protein 1.3 2.3 0.9
SA1659 prsA peptidyl-prolyl cis/trans isomerase 
homologue
Protein folding 10.8 18.1 10.0 33.3
SA1691 sgtB hypothetical protein, similar to penicillin-
binding protein 1A/1B
Cell wall related genes 13.1 8.8 4.8 9.7
SA1700 vraR two-component response regulator RNA synthesis – 
Regulation
13.3 8.0 7.3 17.3
SA1701 vraS two-component sensor histidine kinase Sensors 
(signal transduction)
11.7 8.9 5.8 17.0
SA1702 conserved hypothetical protein 10.4 9.4 4.4 12.2
SA1703 hypothetical protein 31.6 24.8 6.8 45.4
SA1711 hypothetical protein, similar to DNA-
damage inducible protein P
DNA replication, 
modification, repair
2.2 1.6 3.4
SA1712 conserved hypothetical protein 24.7 21.0 5.0 29.4
SA1926 murZ UDP-N-acetylglucosamine 1- 
carboxylvinyl transferase 2
Cell wall related genes 3.2 4.4 3.9 6.1
SA2103 hypothetical protein, similar to lyt 
divergon expression attenuator LytR
RNA synthesis – 
Regulation
6.4 6.1 4.4 8.0
SA2113 hypothetical protein 14.9 11.8 4.9 11.4
SA2146 tcaA TcaA protein 3.3 1.6 2.2 4.0
SA2220 conserved hypothetical protein 7.0 12.2 3.7 21.4
SA2221 hypothetical protein 25.6 18.3 5.2 42.7
SA2222 hypothetical protein, similar to TcaB Protein transport and 
binding
1.2 0.6 1.0
SA2296 hypothetical protein, similar to 
transcriptional regulator MerR
RNA synthesis – 
Regulation
8.1 10.4 3.9 5.5
SA2297 hypothetical protein, similar to GTP-
pyrophosphokinase
Nucleotide, nucleic acid 
metabolism
9.1 14.1 3.9 10.3
SA2298 conserved hypothetical protein 1.8 2.2 1.9
SA2413 sulfite reductase flavoprotein (NADPH) Metabolism of sulfur 1.7 2.2 2.3
SA2480 drp35 drug responsive protein 35 2.7 3.4 2.8 2.8
1 Significant changes of gene expression were determined by implementing SAM (significance analysis of microarrays; http://www-stat.stanford.edu/
~tibs/SAM/) [37].
2 Fold change in transcript level indicated as mean of the "median of ratios" compared to control cells. Fold change in bold = classified as 
"significantly" regulated in this strain by SAM.BMC Microbiology 2008, 8:186 http://www.biomedcentral.com/1471-2180/8/186
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qRT-PCR (Fig. 2A). In the presence of 0.5 × MIC of mersa-
cidin, a strong induction of vraS transcription (16- to 26-
fold) was observed in all strains tested. Even 0.15 × MIC
of mersacidin considerably induced vraS gene transcrip-
tion in strain SA137/93G (5.6-fold) and strain SG511
(3.4-fold) (strain SA137/93A not tested). As a control,
strain SA137/93G was incubated with subinhibitory con-
centrations of vancomycin (4 μg/ml, 2.75 μM, 0.5 × MIC).
Here, no induction was visible by qRT-PCR. This is also
confirmed by earlier studies of other groups who
employed multiple MICs (8 to 10 × MICs) of cell wall
affecting agents like vancomycin, oxacillin or bacitracin to
induce the cell wall stress response [12-14], while low
inhibitory or subinhibitory concentrations of vancomycin
or oxacillin did not lead to an induction [14,25,26]. Like-
wise, an induction of the cell wall stress response could
not be observed for the lantibiotic nisin at inhibitory con-
centrations [16]. Nisin acts by fast depolarization of the
cell membrane as a cause of lipid II-based pore formation
rather than by inhibition of cell wall biosynthesis [17,28].
Thus, the bacteria will be rapidly inactivated by nisin
which prevents an adequate response to cell wall damage
through the VraSR-stimulon. Hence, mersacidin turned
out to be a strong inducer of the cell wall stress response
in S. aureus compared to other substances like vancomy-
cin, oxacillin, bacitracin and nisin.
A comparison of the transcript levels of vraSR of all tested
strains showed that the levels did not vary significantly
between the strains (Fig. 2A). Since the vraSR genes have
been found to be more highly expressed in some VISA
compared to VSSA, the VraSR TCRS has been proposed to
be involved in the VISA-type resistance mechanism via
contribution to cell wall thickening [14,29] and the dele-
tion of the vraSR locus has been described to influence the
development of resistance towards glycopeptides and β-
lactams [12]. However, the cell wall stress response was
similarly induced upon mersacidin treatment in the VISA
strains as well as in the susceptible strain in our studies
and all strains showed equal basal transcript levels. Inter-
estingly, the induction of VraSR did not depend on the
absolute concentration of mersacidin in the medium but
seemed to be triggered by the stress itself, since 0.5 μg/ml
of mersacidin massively induced the cell wall stress
response in the susceptible strain SG511 (here 0.5 μg/ml
correspond to 0.5 × MIC mersacidin, Fig. 2A), while vraS
transcription levels were not significantly affected in strain
SA137/93G (for this strain 0.5 μg/ml correspond to 0.02
× MIC mersacidin). Therefore, the VraSR TCRS might have
evolved as a damage-sensing system that is indirectly
induced as a cause of cell wall damage rather than a drug
sensing system that recognizes the drug itself at defined
concentrations. This is also indicated by findings showing
that VraSR responds to various cell wall-active antibiotics
as well as other conditions of cell wall stress. In this
Gene regulatory response of S. aureus strains SA137/93A, SA137/93G and SG511 to the lantibiotic mersacidin Figure 2
Gene regulatory response of S. aureus strains SA137/93A, SA137/93G and SG511 to the lantibiotic mersacidin. 
(A) qRT-PCR of vraS gene induction in response to subinhibitory concentrations of mersacidin and vancomycin (control). (B) 
qRT-PCR of vraE gene expression upon mersacidin treatment. The qRT-PCR values represent the mean of at least two inde-
pendent experiments. Quantitative data are presented in relation to 106 copies of the housekeeping gene gyrB. Fold changes 
were calculated in relation to the untreated control cells, i. e. transcription levels in the absence of mersacidin.
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regard, the bacitracin-dependent induction of the LiaRS
TCRS in Bacillus subtilis, a close homologue of VraSR, also
indicated a damage-sensing mechanism [30]. This sup-
ports the idea of VraSR being a common accelerator sys-
tem of peptidoglycan synthesis [12], which reacts to
perturbations of cell wall integrity.
Extensive upregulation of the vraDE ABC transporter 
genes and the effect of VraDE on the sensitivity towards 
mersacidin
The presence of mersacidin significantly influenced the
regulation of several genes coding for hypothetical ABC
transporters such as SA0192, vraFG and vraDE (see Addi-
tional file 1 and Additional file 2). Indeed, the most
prominent event of gene regulation involved the upregu-
lation of vraDE (40 to 70-fold in the microarray studies).
The induction of vraDE gene transcription was further ver-
ified via qRT-PCR (Fig. 2B). Upon incubation with 0.5 ×
MIC, vraDE expression was induced 76 to 79-fold in strain
SA137/93A and SA137/93G, respectively. In the suscepti-
ble strain SG511, the transcript level of the vraDE genes
rose almost 1700-fold upon incubation with mersacidin.
This transporter has been previously shown to be induci-
ble by vancomycin and cationic AMPs (CAMPs)
[20,29,31] and seems to be involved in the increased
resistance towards bacitracin and the human β-defensin 3
(hBD3) in S. aureus [20]. However, the regulation under-
lying vraDE induction has not been identified yet. The
VraSR TCRS does not seem to be solely involved in the
upregulation of vraDE transcription as knock-out muta-
tions of the respective gene locus did not lead to an altered
expression of the vraDE genes [12]. The upregulation to
such an extent might indicate that VraDE plays a critical
role in the staphylococcal defense against mersacidin,
especially since resistance is conferred by an ABC trans-
porter in the producer strain of mersacidin [32].
To test whether VraDE is able to transport mersacidin out
of the cell membrane and therefore supports a resistance
phenotype, the growth behaviour and MICs of a vraE
knock-out mutant of S. aureus SG511 [20] and its parent
strain were examined in the presence of the lantibiotic.
Since S. aureus SG511ΔvraE had displayed significantly
reduced resistance to bacitracin and the lantibiotics nisin
and Pep5 [20], VraDE was considered to be functional in
the parent strain. Unexpectedly, S. aureus SG511ΔvraE did
not show increased susceptibility towards mersacidin nei-
ther in growth curve recordings (data not shown) nor in
MIC studies (MIC of SG511ΔvraE: 1 μg/ml; SG511: 1 μg/
ml). Subsequent nucleotide sequencing of the vraDE
genes including the promoter region revealed, that the -35
and the -10 region as well as the ribosomal binding site
and the vraD gene were highly conserved in strains SA137/
93A and SG511 (100% sequence identity) and that the
vraE gene showed 95.7% sequence identity with mostly
conservative amino acid substitutions (data not shown).
Therefore, VraDE is unlikely to contribute to mersacidin
resistance, presumably because it is unable to transport
the lantibiotic. This could be due to the properties of mer-
sacidin which is globular, neutral and non-membrane dis-
turbing. Since VraDE has been shown to predominantly
transport linear, cationic, membrane interacting com-
pounds, it might be unable to facilitate the transport of
other antimicrobials as also shown for chloramphenicol
and oxacillin [20]. However, it cannot be ruled out that
the knockout phenotype is indiscernible through the
activity of another ABC transporter.
Influence of a thickened cell wall of S. aureus on the 
activity of mersacidin
The VISA strains tested here are characterized by a cell wall
with an increased thickness, which is also formed in the
absence of antibiotics [18]. Actually, vancomycin inter-
mediate resistance partly relies on an increase in cell wall
material [18,21,22], which might result from an activated
cell wall metabolism. In order to estimate the influence of
an increased cell wall thickness on the action of mersaci-
din, cells with increased amounts of peptidoglycan were
obtained by incubation in resting medium (RM) for two
hours. Cell wall resting medium allows the biosynthesis
of excess cell wall material, while the absence of essential
amino acids prohibits growth. Controls were performed
in RM devoid of glucose (RM-g), which is necessary for
synthesis of extra cell wall material [21,33]. After incuba-
tion of the cells in RM or RM-g, the susceptibility to mer-
sacidin was tested. Vancomycin served as control in our
studies. In the case of mersacidin, the incubation in the
presence of glucose did not decrease the susceptibility of
S. aureus SG511 and of the VISA strains SA137/93A and
SA137/93G (Fig. 3), whereas the efficacy of vancomycin
was always lower against cells that had been incubated in
the presence of glucose. In strain SG511, mersacidin was
even more effective than vancomycin, which was not the
case for the strains SA137/93A and SA137/93G.
The above results demonstrate that the cell wall thickness
does not impact on the antibiotic efficacy of mersacidin.
Thus, the induction of the cell wall stress response at low
mersacidin concentrations may be partly explained by the
differences that characterize the interactions of mersacidin
and vancomycin with the cell envelope. While mersacidin
and vancomycin both target lipid II, vancomycin acts by
binding to the D-alanyl-D-alanine terminus of the peptide
side chain of lipid II. In a thickened cell wall, increased
amounts of free D-alanyl-D-alanine termini provide false
target sites for vancomycin binding. This results in a
decreased diffusion velocity of vancomycin through the
cell wall, the "clogging effect" [21], and only those vanco-
mycin molecules that are not trapped in the cell wall will
reach lipid II. In contrast to vancomycin, mersacidin com-BMC Microbiology 2008, 8:186 http://www.biomedcentral.com/1471-2180/8/186
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plexes the sugar phosphate head group of the peptidogly-
can precursor lipid II, which is only present in the
membrane and experiments with radiolabeled mersacidin
have confirmed that it does not bind to isolated cell walls
[7]. In in vitro cell wall biosynthesis systems, the effective
concentration of mersacidin is in the same range as that of
vancomycin [34]. Therefore, although nearly similar
molar concentrations (2.175 μM mersacidin (0.15 × MIC)
and 2.75 μM vancomycin (0.5 × MIC)) of the two antibi-
otics were used in the induction assays, less vancomycin
than mersacidin molecules may have been available at the
cell membrane for the binding of lipid II. This effect could
explain why higher concentrations of vancomycin have to
be employed in order to induce the cell wall stress
response and why lower initial concentrations of mersaci-
din may be sufficient for an effective induction of VraSR.
Conclusion
Mersacidin strongly induces the cell wall stress response
of S. aureus even at very low concentrations as compared
to other antibiotics like nisin, vancomycin, bacitracin or
oxacillin, thereby reflecting its unique mode of action.
Our results underline the important role of lipid II in this
context and demonstrate that the induction of the cell
wall stress response is not in every case dependent on
inhibitory concentrations of cell wall-active substances.
Furthermore, mersacidin represents a molecule that seems
not to be a substrate for the multidrug resistance trans-
porter VraDE which apparently functions in the first line
bacterial counter strategy against bacitracin and cationic
toxic compounds. Biochemical characterization of VraDE
and related transporters will test this hypothesis and may
provide directions for circumventing the activity of resist-
ance transporters through structural modification of anti-
biotics.
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Influence of cell wall thickness on mersacidin activity. 
The influence of an increased cell wall thickness on the effi-
cacy of mersacidin was studied for the S. aureus strains 
SA137/93A (A), SA137/93G (B) and SG511 (C). To this end, 
S. aureus cells were incubated in resting medium supple-
mented with glucose (RM+g), which allows the synthesis of 
increased amounts of peptidoglycan, or in the absence of glu-
cose (RM-g), which prevents synthesis of extra cell wall 
material. The data represent the optical density (600 nm) of 
RM-preincubated S. aureus cells after treatment with differ-
ent concentrations of mersacidin. Vancomycin served as a 
control. Black triangle, mersacidin/RM+g; white triangle, mer-
sacidin/RM-g; black square, vancomycin/RM+g; white square, 
vancomycin/RM-g.BMC Microbiology 2008, 8:186 http://www.biomedcentral.com/1471-2180/8/186
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Methods
Bacterial strains, growth conditions and antimicrobial 
susceptibility testing
Bacterial strains and plasmids are listed in Table 2. S.
aureus strains were cultured in brain heart infusion (BHI)
medium (Becton-Dickinson GmbH, Heidelberg, Ger-
many) at 37°C with aeration unless indicated otherwise.
MIC determinations of mersacidin (Hoechst, Frankfurt
am Main, Germany) were performed in polystyrene
round bottom microtiter plates (Greiner, Frickenhausen,
Germany) using BHI broth. An inoculum of 5 × 105 CFU/
ml was employed in the arithmetic broth microdilution
method. All experiments were done in triplicate. For
growth analysis and RNA preparations, S. aureus cultures
were diluted 200-fold from overnight cultures and grown
to exponential phase until they reached an OD600 of 0.5 in
BHI broth. Then, mersacidin was added as indicated, and
the cultures were further grown to an OD600 of 1.0 for
RNA preparations (~30 min) or longer to assess growth
behavior. CaCl2 was supplemented to all cultures to a
final concentration of 1 mM, since Ca2+-ions enhance the
bactericidal effect of mersacidin [35,36].
Preparation of total RNA
Exponential-phase cultures of 10 ml were grown as afore-
mentioned and stabilized by incubation with two vol-
umes of prewarmed RNAprotect Bacteria Reagent
(Qiagen, Hilden, Germany) for 5 min at 37°C. The cul-
ture was subsequently harvested by centrifugation and the
pellets were shock-frozen in liquid nitrogen and kept at -
70°C. The cells were lysed in the presence of 400 μg/ml
lysostaphin (Genmedics, Reutlingen, Germany) and total
RNA was extracted using the PrestoSpin R bug kit includ-
ing DNase I treatment (Molzym, Bremen, Germany) fol-
lowing the manufacturer's instructions. Quality and
quantity of total RNA were determined by agarose gel elec-
trophoresis and measured by using the Nanodrop spectro-
photometer (Nanodrop Technologies, Wilmington,
USA).
Synthesis of CyDye-3 and CyDye-5 labeled cDNA for 
microarray experiments
Fluorescence-labeled single-stranded cDNA was obtained
by reverse transcription of total RNA. To this end, aliquots
of total RNA preparations from three different cultures of
the respective experiment were pooled to a total amount
of 9 μg (3 μg each) and transcribed into cDNA using 100
units (U) of BioScript reverse transcriptase (Bioline, Luck-
enwalde, Germany) following the manufacturer's instruc-
tions. For direct cDNA labeling, the total reaction volume
of 40 μl contained 75 μg/ml pd(N)6 random hexamers
(GE Healthcare – Amersham, NJ, USA), 0.1 mM CyDye3-
or CyDye5-dCTPs (GE Healthcare – Amersham) aside
from 0.2 mM dCTP, 0.5 mM dATP, 0.5 mM dTTP, 0.5 mM
dGTP and 25 U/ml RNase-OUT (Invitrogen, Karlsruhe,
Germany). RNA was degraded by alkaline hydrolysis at
Table 2: Bacterial strains, plasmids and primers used in this study
Strain, plasmid or primer Relevant characteristic(s)/primer sequence Reference(s) or source
Strains
S. aureus
SG511 Susceptible control strain RKI Berlin, Germany
SA137/93A Clinical hVISA isolate; METr, Northern German epidemic MRSA [18]
SA137/93G Spontaneous mutant of SA137/93A, ΔSCC mec (METs), ΔtcaA [18,19]
SG511ΔvraE vraE-defective mutant of strain SG511 [20]
Plasmids
pUC19gyrB pUC19 (Ampr), carrying a 560 bp internal fragment of gyrB; external plasmid standard for qRT-
PCR
[38]
Primers
a) Oligonucleotide primers used for the synthesis of external qRT-PCR standards
vraE-1 TCTCATATGACATTTAACCATATCGTTTTC This study
vraE-2 TAACTCGAGAATGGTTTTCTTAATCAATTTGTTTG This study
vraS-1 TTACATATGAACCACTACATTAGAACAAT This study
vraS-2 AATAAGCTTATCGTCATACGAATCCTCCT This study
b) Oligonucleotide primers used for qRT-PCR
gyrB-297 TTAGTGTGGGAAATTGTCGATAAT [39]
gyrB-547 AGTCTTGTGACAATGCGTTTACA [39]
vraE-1-RT2 GTAACTGTATTGTGTTTCGCGGC This study
vraE-2-RT2 TGATGGCATTGTTGCCTGTTACC This study
vraS-1-RT GTTGGTTCGGTACTCGCATA This study
vraS-2-RT CTCGAGCTAGTCTTTGACGTTC This study
Abbreviations: MET, methicillin; Amp, ampicillin; r, resistant; s, susceptibleBMC Microbiology 2008, 8:186 http://www.biomedcentral.com/1471-2180/8/186
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65°C and fluorescence-labeled cDNA was purified using
the MinElute PCR purification kit (Qiagen). cDNA syn-
thesis and CyDye3/CyDye5 incorporation were verified
by using the Nanodrop spectrophotometer (Nanodrop
Technologies).
Microarray hybridization and analysis
Microarray-based transcriptional profiling by competitive
hybridization of fluorescence-labeled cDNA was per-
formed by using the custom PCR product full-genome
chip sciTracer (Scienion, Berlin, Germany). Each experi-
ment was performed 4 times including a dye swap result-
ing in four chips per competitive comparison to increase
reproducibility. Only strain SA137/93G incubated with
0.15 × MIC of mersacidin was reproduced in duplicate. All
hybridizations were done with equal amounts of cDNA
probes displaying similar picomoles of incorporated dye.
Fluorescence-labeled cDNA probes were mixed in hybrid-
ization buffer (Scienion) in a total volume of 55 μl, dena-
tured at 95°C for 2 min and subsequently applied to the
microarray slide followed by incubation at 42°C for 72
hours under humidified conditions according to the man-
ufacturer's instructions. Hybridized microarrays were
washed at room temperature in SSC buffer with decreas-
ing salt concentrations (1 × SSC/0.3% SDS for 5 min, 0.2
× SSC for 5 min, 0.06 × SSC for 30s). For image capture,
the microarray was scanned with a GenePix 4000B scan-
ner (Axon Instruments/Distribution by Biozyme Scientific
GmbH, Hessisch Oldendorf, Germany). The TIFF images
were analyzed with GenePixPro4.1 software (Axon Instru-
ments). The actual signal intensity was calculated by using
the mean of the "median of ratios" of the individual spot.
The data sets were then normalized by using Acuity 3.1
software (Axon Instruments) and by applying the LOW-
ESS algorithm. Significant changes of gene expression
were determined by implementing SAM (significance
analysis of microarrays; http://www-stat.stanford.edu/
~tibs/SAM/; [37]) using the one class response and a false
discovery rate of < 1% with a medium number of falsely
called significant genes of < 1.
Microarray data accession number
Additional information on the microarray platform as
well as the processed and raw microarray data of this
study have been deposited in NCBI's Gene Expression
Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/ to
be found under the GEO Series accession number
GSE9261.
Microarray validation and transcript quantification by 
Real-Time PCR
The LightCycler instrument (Roche Diagnostics, Man-
nheim, Germany) was employed to generate quantitative
transcription data by measuring sample amplification
during the log-linear phase of the PCR. Therefore, total
RNA preparations (3 μg) were transcribed into cDNA
using BioScript reverse transcriptase (Bioline) and pd(N)6
random hexamers (GE Healthcare) following the manu-
facturers' instructions. Quantitative Real-Time PCR (qRT-
PCR) was performed by using the LightCycler FastStart
DNA Master SYBR Green I kit (Roche Diagnostics) accord-
ing to the manufacturer's instructions. For all experi-
ments, the amount of transcripts was determined from the
appropriate standard curve and the target concentration
was expressed in relation to the concentration of the con-
stitutively expressed housekeeping gene gyrB. Each stand-
ard curve was generated by assaying gene specific PCR
product or plasmid templates. The specific primers, which
were used for the synthesis of external LightCycler stand-
ards or for qRT-PCR of the target genes and the endog-
enous control gyrB, are listed in Table 2. To control quality
and reproducibility of the qRT-PCR data, at least two dif-
ferent cDNA probes were synthesized employing RNA
preparations from independent cultures for every condi-
tion. The PCR products were verified by melting curve
analysis and ethidium bromide staining on agarose gels.
Growth experiments after incubation in resting medium
To obtain cells with different amounts of peptidoglycan,
S. aureus cultures were grown to an OD600 of 0.5 in 35 ml
BHI, harvested, washed and resuspended in 35 ml pre-
warmed resting medium (RM). RM contains salts, amino
acids (glutamic acid 0.3 g/l, aspartic acid 0.1 g/l, lysine 0.1
g/l, alanine 0.2 g/l, cystine 0.2 g/l) and glucose (10 g/l)
necessary for cell wall biosynthesis but not sufficient for
growth and division. As a control, the omission of glucose
(RM-g) also stopped cell wall biosynthesis [21,33]. After 2
h of incubation at 37°C, the cells were harvested again,
resuspended in 30 ml fresh BHI broth and aliquots of 3 ml
were distributed into tubes containing different concen-
trations of mersacidin or vancomycin (control). The tubes
were incubated overnight on a shaker and after 20 h the
optical density (600 nm) of the cultures was measured.
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